For melanoma, T-VEC is being evaluated as a single-agent treatment in four different trials, including expanded access trials (NCT0214751, NCT02297529) and a Phase II study evaluating the correlation between CD8+ cells and objective response rate after T-VEC treatment (NCT 02366195). The gene discussed is CD8A; the disease is melanoma.